Log In
BCIQ
Print this Print this
 

Coreg CR, carvedilol

  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionControlled-release formulation of adrenergic receptor beta blocker Coreg
Molecular Target Adrenergic receptor beta (ADRB)
Mechanism of ActionAdrenergic receptor beta (ADRB) antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationHeart failure
Indication DetailsTreat heart failure
Regulatory Designation
PartnerAvadel Pharmaceuticals plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$26.3M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/28/2014

$26.3M

Undisclosed

0

Get a free BioCentury trial today